Skip to main content

Luminex Gains Rights to ViroNovative IP for Use in Respiratory Viral Panel

NEW YORK (GenomeWeb News) – Luminex said today that it has signed an agreement with Dutch diagnostic developer ViroNovative that gives it worldwide rights to use the company’s human metapneumovirus intellectual property in its xTAG Respiratory Viral Panel.
Luminex said that its distributors and end-user customers around the world also have rights to use the ViroNovative IP under the terms of the agreement.
"Having this license as part of our xTAG RVP assay is important to us as it allows our customers to use this cutting-edge test without the need to individually secure rights to this intellectual property," said Jeremy Bridge-Cook, vice president of Luminex Molecular Diagnostics, in a statement.  
Luminex received 510(k) clearance for the xTAG RVP assay from the US Food and Drug Administration in January. The test was cleared for the detection of 12 viruses and viral subtypes, including hMPV.
ViroNovative is an Erasmus University spin-out that is focused on developing diagnostics, vaccines, and antivirals for hMPV. The virus, first characterized in 2001 by company founders, causes flu-like symptoms and is thought to be the second-most-common cause of lower respiratory infection in young children.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.